Stenosis

Silk Road Medical Names Chas McKhann Chief Executive Officer

Retrieved on: 
Thursday, November 2, 2023

SUNNYVALE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road” or the “Company”), a company focused on reducing the risk of stroke and its devastating impact, today announced that Chas McKhann has been appointed Chief Executive Officer (CEO), effective immediately.

Key Points: 
  • SUNNYVALE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road” or the “Company”), a company focused on reducing the risk of stroke and its devastating impact, today announced that Chas McKhann has been appointed Chief Executive Officer (CEO), effective immediately.
  • “Chas is a skilled and experienced leader with a track record of effectively building and scaling medical device businesses into underpenetrated markets.
  • We are excited to welcome him to Silk Road,” said Jack Lasersohn, Chairman of the Board of Directors.
  • Under his leadership, Silk Road remains committed to the same mission, vision, and values that have guided it since its founding.

Hagens Berman- Silk Road Medical (SILK) Stock Tanks After Revenues Lowered and CEO Leaves

Retrieved on: 
Tuesday, October 31, 2023

SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Hagens Berman encourages Silk Road Medical, Inc. (NASDAQ: SILK) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Hagens Berman encourages Silk Road Medical, Inc. (NASDAQ: SILK) investors who suffered substantial losses to submit your losses now .
  • On Oct. 10, 2023, Silk Road announced, without explanation, that: (1) its Q3 2023 revenues were expected to be below Q2 revenues; and (2) it significantly reduced its expected FY 2023 revenues.
  • If you invested in Silk Road Medical and have significant losses, or have knowledge that may assist the firm’s investigation, submit your losses now .
  • »
    If you’d like more information and answers to frequently asked questions about the Silk Road Medical investigation, read more »
    Whistleblowers: Persons with non-public information regarding Silk Road Medical should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silk Road Medical, Inc. - SILK

Retrieved on: 
Friday, October 27, 2023

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Silk Road Medical, Inc. (“Silk Road” or the “Company”) (NASDAQ: SILK).

Key Points: 
  • NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Silk Road Medical, Inc. (“Silk Road” or the “Company”) (NASDAQ: SILK).
  • The investigation concerns whether Silk Road and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On October 10, 2023, Silk Road announced that its second quarter 2023 revenues were expected to be below its first quarter revenues and significantly reduced its expected full year 2023 revenues.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Contego Medical Announces One-Year Outcomes From the Performance II Carotid Stent Trial

Retrieved on: 
Wednesday, November 1, 2023

Contego Medical Inc., a company dedicated to improving patient outcomes and procedural efficiency in the treatment of carotid and peripheral vascular disease, today announced the presentation of late-breaking clinical results from the PERFORMANCE II carotid stent trial at the annual VIVA (Vascular InterVentional Advances) multidisciplinary vascular education conference.

Key Points: 
  • Contego Medical Inc., a company dedicated to improving patient outcomes and procedural efficiency in the treatment of carotid and peripheral vascular disease, today announced the presentation of late-breaking clinical results from the PERFORMANCE II carotid stent trial at the annual VIVA (Vascular InterVentional Advances) multidisciplinary vascular education conference.
  • PERFORMANCE II is a prospective, multicenter study evaluating the safety and effectiveness of the Neuroguard IEP® System in 305 patients at 40 clinical sites.
  • The Neuroguard closed cell stent utilizes FlexRingTM technology, providing optimized radial strength and flexibility while leveraging nitinol’s proven long-term material performance.
  • “The IEP platform, as demonstrated in the PALADIN, PERFORMANCE I and PERFORMANCE II studies, meaningfully advances stroke protection for patients.

ConcertAI's TeraRecon Broadens Collaboration with Avicenna.AI to Offer AI-Driven Care Coordination for Pulmonary Embolism and Aortic Disease

Retrieved on: 
Wednesday, November 1, 2023

Together, they will provide global solutions that leverage artificial intelligence to enhance care coordination and improve patient triage for individuals afflicted with pulmonary embolism (PE) and aortic dissection (AD).

Key Points: 
  • Together, they will provide global solutions that leverage artificial intelligence to enhance care coordination and improve patient triage for individuals afflicted with pulmonary embolism (PE) and aortic dissection (AD).
  • This collaboration aims to expedite clinical decision-making and optimize patient care for these critical medical conditions.
  • "We are excited to empower TeraRecon users worldwide with our groundbreaking AI-driven solutions for the care coordination of pulmonary embolism and aortic dissection," said Cyril Di Grandi, Chief Executive Officer of Avicenna.AI.
  • We eagerly anticipate extending the benefits of our pulmonary embolism and aortic dissection triage tools to the emergency room and beyond."

Silk Road Medical (SILK) Stock Tanks After Revenues Lowered and CEO Leaves – Hagens Berman Firm Encourages Investors with Substantial Losses to Contact its Attorneys

Retrieved on: 
Wednesday, October 25, 2023

On Oct. 10, 2023, Silk Road announced, without explanation, that: (1) its Q3 2023 revenues were expected to be below Q2 revenues; and (2) it significantly reduced its expected FY 2023 revenues.

Key Points: 
  • On Oct. 10, 2023, Silk Road announced, without explanation, that: (1) its Q3 2023 revenues were expected to be below Q2 revenues; and (2) it significantly reduced its expected FY 2023 revenues.
  • This news drove the price of Silk Medical shares down nearly 50% on Oct. 11, 2023.
  • “We’re focused on investors’ losses and investigating whether Silk Road may have misled investors about the effect of the NCD’s decision on TCAR-related revenues,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Silk Road Medical and have significant losses, or have knowledge that may assist the firm’s investigation, submit your losses now .

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silk Road Medical, Inc. - SILK

Retrieved on: 
Thursday, October 19, 2023

NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Silk Road Medical, Inc. (“Silk Road” or the “Company”) (NASDAQ: SILK).

Key Points: 
  • NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Silk Road Medical, Inc. (“Silk Road” or the “Company”) (NASDAQ: SILK).
  • The investigation concerns whether Silk Road and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On October 10, 2023, Silk Road announced that its second quarter 2023 revenues were expected to be below its first quarter revenues and significantly reduced its expected full year 2023 revenues.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Silk Road Medical (SILK) Investors with Substantial Losses Encouraged to Contact Hagens Berman, National Trial Attorneys: Firm Investigating Possible Securities Law Violations

Retrieved on: 
Monday, October 16, 2023

SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Hagens Berman encourages Silk Road Medical, Inc. (NASDAQ: SILK) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Hagens Berman encourages Silk Road Medical, Inc. (NASDAQ: SILK) investors who suffered substantial losses to submit your losses now .
  • Hagens Berman is investigating potential violations of the securities laws.
  • “We’re focused on investors’ losses and investigating whether Silk Road may have misled investors about the effect of the NCD’s decision on TCAR-related revenues,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Silk Road Medical and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .

Silk Road Medical Stock (SILK) Nosedives on CEO Departure and Revenue Shortfall

Retrieved on: 
Wednesday, October 11, 2023

SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman encourages Silk Road Medical, Inc. (NASDAQ: SILK) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman encourages Silk Road Medical, Inc. (NASDAQ: SILK) investors who suffered substantial losses to submit your losses now .
  • This news drove the price of Silk Medical shares down nearly 50% on Oct. 11, 2023.
  • If you invested in Silk Road Medical and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .
  • Whistleblowers: Persons with non-public information regarding Silk Road Medical should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.

Silk Road Medical Announces Retirement of CEO Erica Rogers

Retrieved on: 
Tuesday, October 10, 2023

SUNNYVALE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that CEO Erica Rogers plans to retire from the Company following the completion of a succession process. The Company is working with Spencer Stuart, a leading executive search firm. To ensure a smooth transition, Ms. Rogers will remain as President and CEO of the Company until her successor is appointed.

Key Points: 
  • SUNNYVALE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that CEO Erica Rogers plans to retire from the Company following the completion of a succession process.
  • To ensure a smooth transition, Ms. Rogers will remain as President and CEO of the Company until her successor is appointed.
  • “I’d like to thank Erica for her tremendous contributions to Silk Road over the last 11 years.
  • “The Silk Road Medical senior leadership team and Board of Directors are well-prepared for Erica’s transition.